Complex Dendrimer–Lyotropic Liquid Crystalline Systems: Structural Behavior and Interactions

Abstract

The incorporation of dendrimer into three lyotropic liquid crystalline (LLCs) mesophases is demonstrated for the first time. A second generation (G2) of poly(propylene imine) dendrimer (PPI) was solubilized into lamellar, diamond reverse cubic, and reverse hexagonal LLCs composed of glycerol monooleate (GMO), and water (and D-α-tocopherol in the H(II) system). The combination of PPI with LLCs may provide an advantageous drug delivery system. Cross-polarized light microscope, small-angle X-ray scattering (SAXS), and attenuated total reflectance Fourier transform infrared (ATR-FTIR) were utilized to study the structural behavior of the mesophases, the localization of PPI within the system, and the interactions between the guest molecule and the system's components. It was revealed that PPI-G2 functioned as a "water pump", competing with the lipid headgroups for water binding. As a result, L(α)→H(II) and Q(224)→H(II) structural shifts were detected (at 10 wt % PPI-G2 content), probably caused by the dehydration of monoolein headgroups and subsequent increase of the lipid's critical packing parameter (CPP). In the case of H(II), as a result of the balance between the dehydration of the monoolein headgroups and the significant presence of PPI within the interfacial region, increasing the quantity of hydrogen bonds, no structural transitions occurred. ATR-FTIR analysis demonstrated a downward shift of the H-O-H (water), as a result of PPI-G2 embedment, suggesting an increase in the mean water-water H-bond angle resulting from binding PPI-G2 to the water network. Additionally, the GMO hydroxyl groups at β- and γ-C-OH positions revealed a partial interaction of hydrogen bonds with N-H functional groups of the protonated PPI-G2. Other GMO interfacial functional groups were shown to interact with the PPI-G2, in parallel with the GMO dehydration phenomenon. In the future, these outcomes can be used to design advanced drug delivery systems, allowing administration of dendrimers as a therapeutic agent from LLCs.